AP Substrate CDP Star Tropix
- Known as:
- AP Substrate CDP Star Tropix
- Catalog number:
- 40-5010-10
- Product Quantity:
- 10ml
- Category:
- -
- Supplier:
- Gene Link
- Gene target:
- Substrate CDP Star Tropix
Related genes to: AP Substrate CDP Star Tropix
- Gene:
- STAR NIH gene
- Name:
- steroidogenic acute regulatory protein
- Previous symbol:
- -
- Synonyms:
- StAR, STARD1
- Chromosome:
- 8p11.23
- Locus Type:
- gene with protein product
- Date approved:
- 1996-04-24
- Date modifiied:
- 2016-10-05
Related products to: AP Substrate CDP Star Tropix
1,2-Dioleoyl-3-(pyren-1-yl) decanoyl-rac-glycerol, Fluorescent Lipase Substrate, 1mg Ampule1,2-Dioleoyl-3-(pyren-1-yl) decanoyl-rac-glycerol, Fluorescent Lipase Substrate, 1mg Ampule1,2_Dioleoyl_3_(pyren_1_yl) decanoyl_rac_glycerol, Fluorescent Lipase Substrate, 1mg Ampule1X TMB ELISA Substrate Solution 100 mL2 CDC25C, CHK1 and CHK2 Substrate, phosphorylated2', 7'-Dichlorofluorescin diacetate, Enzyme Substrate, 25mg2', 7'-Dichlorofluorescin diacetate, Enzyme Substrate, 25mg2', 7'_Dichlorofluorescein diacetate, Enzyme Substrate, 25mg2, 7-Dichlorofluorescein di-galactoside, Fluorescent substrate for measuring galactosidase and galactocerebrosidase activity, 25mg2, 7-Dichlorofluorescein di-galactoside, Fluorescent substrate for measuring galactosidase and galactocerebrosidase activity, 25mg2, 7_Dichlorofluorescein di_galactoside, Fluorescent substrate for measuring galactosidase and galactocerebrosidase activity, 25mg2-Chloro-4-nitrophenyl a-L-fucopyranoside (CNPF) extrapure for biochemistry (A substrate for the enzyme a -L-fucosidase (AFU))2-Chloro-4-nitrophenyl-beta-D-cellobioside, Fluorescent Substrate for Cellulases, 25mg2-Chloro-4-nitrophenyl-beta-D-cellobioside, Fluorescent Substrate for Cellulases, 25mg2-Chloro-4-nitrophenyl-beta-D-lactoside, Fluorescent Substrate for Cellulases, 25mg Related articles to: AP Substrate CDP Star Tropix
- - Source: PubMed
Publication date: 2026/04/17
Ng Daniel Zhi WeiYap Gaik ChinTay Carina Jing XuanHuang Chiung-HuiZhao SiyanLow AdrianTham Elizabeth HuiwenLoo Evelyn Xiu LingShek Lynette PGoh AnneChong Kok WeeGoh Si HuiCheng Zai RuVan Bever Hugo P STeoh Oon HoeLee Yung SengYap FabianTan Kok HianChong Yap-SengChan Shiao-YngEriksson Johan GunnarGodfrey Keith MLay ChristopheKnol JanSchuster Stephan CLai Jun ShiChong Mary Foong-FongLee Jonathan Wei JieLee Bee WahChan Eric Chun YongTa Le Duc Huy - Structuring liquids can be achieved by the assembly and jamming of particles at the oil-water interface. However, this typically requires surface modification of particles or co-assembly with polymer ligands to enhance interfacial binding energies. Here, we show a simple and robust strategy to structure liquids by using water-soluble, star-shaped β-cyclodextrin (β-CD) derivatives, whose interfacial assembly is driven by supramolecular interactions with oil solvents. Three classes of solvents including alkanes, aromatic hydrocarbons and halohydrocarbons are examined, leading to distinct interfacial binding energies of β-CD derivatives and different liquid structuring and coalescence behaviors. In aromatic hydrocarbon/water biphasic systems, β-CD derivatives form jammed yet porous interfacial assemblies that combine mechanical rigidity with high free volume. As a result, the liquids are shapeable, reconfigurable and capable of arrested coalescence upon gentle contact, opening opportunities for programmable liquid constructs, soft robots, and related applications. - Source: PubMed
Publication date: 2026/04/17
Li PeifanFeng WeixiaoWen YunhuiLuo YuzhengLiu XueqingShi Shaowei - Immunonutrition, once thought to reduce infections in critically ill patients, faced scrutiny in the early 2000s following large trials that showed limited benefits and potential harm, particularly from formulas supplemented with arginine and glutamine. Newer evidence on immune-enhancing diets (IEDs) has prompted a shift toward individualized, precision-based nutrition strategies. Omega-3 fatty acids remain promising, especially in patients with traumatic brain injury or critical illness-induced muscle-wasting. Current guidelines recommend selective use of IEDs, such as in patients with cancer or chronic inflammatory conditions. - Source: PubMed
Publication date: 2026/01/29
Rehani ChaviPelekhaty StacyKozar Rosemary A - Genomic instability is a defining feature of cancer, which arises when the cellular systems that maintain DNA integrity falter, enabling the accumulation of genetic and epigenetic alterations that drive malignant transformation. It is both the architect of cancer's evolution and its Achilles' heel. Targeting genomic instability has reshaped oncology: first through systemic chemotherapy and external beam radiation and then with poly(ADP-ribose) polymerase (PARP) inhibitors in homologous recombination repair-deficient tumors and other DNA damage response targets. Recently, tumor-targeted DNA-damaging platforms, namely antibody-drug conjugates (ADCs) and radiopharmaceuticals, have emerged alongside modern precision medicine strategies to optimize patient selection, develop rational combinations, and widen the therapeutic index. - Source: PubMed
Yap Timothy AManning H CharlesSapra PujaMills Gordon BO'Connor Mark J - A major challenge in advancing neoantigen-targeted therapies lies in the limited capacity of predicted neoantigens to robustly activate CD8 T cells, emphasizing the critical need for comprehensive functional validation before patient vaccination. Here, we provide a direct comparison of neoantigen-specific T cell responses between vaccinated patients with cancer and HLA-matched healthy donors. Despite vaccination, patient-derived T cells recognized only a small fraction of predicted neoantigens, whereas healthy donor T cells consistently exhibited broader and more robust neoantigen reactivity. Furthermore, we successfully expanded neoantigen-specific T cells from allogeneic donors, revealing that their T cell receptors (TCRs) can recognize targets that the patient's own T cells fail to engage with, partly due to poor T cell fitness. Collectively, these results indicate that cancer vaccines may be insufficient to overcome intrinsic defects in patient-derived T cell responses, supporting the use of healthy donor-derived TCRs as a complementary approach. - Source: PubMed
Publication date: 2026/04/17
Teo Hong KaiHan ShutingManoharan ThamizhanbanRen YiCheng Cyrus Zai MingLoo Soon ChaiLin ZhewangLi JiaqiWang Who-WhongKoo Si-LinRethnam MaliniYap Choon KongSiew Bei-EnSoon Gwyneth Shook-TingCheong Wai-KitLee Kai-YinTan Ian Jse-WeiLieske BettinaTan Ker-KanToh Han ChongTan Iain Bee HuatChia Gloryn